Plasma eicosanoid profiling in the course of proprotein convertase Subtilisin-Kexin type 9 inhibition: Insights from a metabolomic analysis

被引：0
|
作者：
Schrutka, L. [1 ]
Hagn, G. [2 ]
Galli, L. [1 ]
Poeschl, A. [1 ]
Seidl, V [1 ]
Ondracek, A. S. [1 ]
Bileck, A. [2 ]
Lang, I [1 ]
Hengstenberg, C. [1 ]
Krychtiuk, K. [1 ]
Speidl, W. [1 ]
Gerner, C. [2 ]
Distelmaier, K. [1 ]
机构：
[1] Med Univ Wien, Vienna, Austria
[2] Univ Wien, Vienna, Austria
来源：
WIENER KLINISCHE WOCHENSCHRIFT | 2022年 / 134卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
11-8
引用
收藏
页码：160 / 161
页数：2
相关论文
共 50 条
  • [31] Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review
    Yuet, Wei C.
    Ebert, Didi
    Jann, Michael
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2021, 12
  • [32] Proprotein convertase subtilisin/kexin type 9 and lipid metabolism
    Spolitu, Stefano
    Dai, Wen
    Zadroga, John A.
    Ozcan, Lale
    CURRENT OPINION IN LIPIDOLOGY, 2019, 30 (03) : 186 - 191
  • [33] Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9
    Kotani, Kazuhiko
    Banach, Maciej
    JOURNAL OF THORACIC DISEASE, 2017, 9 (01) : E78 - E82
  • [34] Depressive Symptoms and Proprotein Convertase Subtilisin/Kexin Type 9
    Macchi, C.
    Buoli, M.
    Favero, C.
    Pesatori, A.
    Vigna, L.
    Corsini, A.
    Sirtori, C.
    Bollati, V.
    Ruscica, M.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (05): : S92 - S92
  • [35] The impact of discontinuing proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors on clinical outcomes
    Tsubata, H.
    Wakana, N.
    Yanishi, K.
    Nakanishi, N.
    Zen, K.
    Nakamura, T.
    Matoba, S.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [36] Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis
    Ferraz-Amaro, I.
    Lopez-Mejias, R.
    Ubilla, B.
    Genre, F.
    Tejera-Segura, B.
    de Vera-Gonzalez, A. M.
    Gonzalez-Rivero, A. F.
    Olmos, J. M.
    Hernandez, J. L.
    Llorca, J.
    Gonzalez-Gay, M. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (06) : 1013 - 1019
  • [37] Proprotein convertase subtilisin/kexin type 9 in kidney disease
    Schmit, David
    Fliser, Danilo
    Speer, Thimoteus
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (08) : 1266 - 1271
  • [38] New developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications
    Seidah, Nabil G.
    CURRENT OPINION IN LIPIDOLOGY, 2016, 27 (03) : 274 - 281
  • [39] Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition-The Dream of Translational Medicine
    Uppugunduri, Chakradhara Rao S.
    George, Melvin
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2016, 67 (02) : 191 - 192
  • [40] Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive HypercholesterolemiaBrief Report
    Thedrez, Aurelie
    Sjouke, Barbara
    Passard, Maxime
    Prampart-Fauvet, Simon
    Guedon, Alexis
    Croyal, Mikael
    Dallinga-Thie, Geesje
    Peter, Jorge
    Blom, Dirk
    Ciccarese, Milco
    Cefalu, Angelo B.
    Pisciotta, Livia
    Santos, Raul D.
    Averna, Maurizio
    Raal, Frederick
    Pintus, Paolo
    Cossu, Maria
    Hovingh, Kees
    Lambert, Gilles
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (08) : 1647 - 1650
12345